{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:21:24Z","timestamp":1793647284117,"version":"4.5.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jaccao.2023.05.011","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T14:00:04Z","timestamp":1690898404000},"page":"613-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Cardiovascular Effects of GnRH Antagonists Compared With Agonists in\u00a0Prostate Cancer"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-2548","authenticated-orcid":false,"given":"Adam J.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwanhee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyuan","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Slovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2772-0695","authenticated-orcid":false,"given":"Sean","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Margel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence H.","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1968-169X","authenticated-orcid":false,"given":"Darryl P.","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestia S.","family":"Higano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2023.05.011_bib1","first-page":"1109","article-title":"Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study","volume":"203","author":"Leong","year":"2020","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jaccao.2023.05.011_bib2","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A\u00a0population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2023.05.011_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12265-019-09942-w","article-title":"Effect of androgen deprivation therapy on metabolic complications and cardiovascular risk","volume":"13","author":"Melloni","year":"2020","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.jaccao.2023.05.011_bib4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.jaccao.2023.05.011_bib5","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.05.011_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2020.06.002","article-title":"Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials","volume":"79","author":"Abufaraj","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.jaccao.2023.05.011_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/ehjcvp\/pvab005","article-title":"The cardiovascular effects of Gnrh antagonists in men with prostate cancer","volume":"8","author":"Cirne","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jaccao.2023.05.011_bib8","first-page":"70","article-title":"Cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: the PRONOUNCE trial study design","volume":"2","author":"Melloni","year":"2020","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.05.011_bib9","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.05.011_bib10","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)","author":"Higgins","year":"2022"},{"key":"10.1016\/j.jaccao.2023.05.011_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1740774520969136","article-title":"Meta-analysis of rare adverse events in randomized clinical trials: Bayesian and frequentist methods","volume":"18","author":"Hong","year":"2021","journal-title":"Clin Trials"},{"key":"10.1016\/j.jaccao.2023.05.011_bib12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/cen.13574","article-title":"Injection testosterone and adverse cardiovascular events: a case-crossover analysis","volume":"88","author":"Layton","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jaccao.2023.05.011_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","article-title":"The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy","volume":"35","author":"Crawford","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.jaccao.2023.05.011_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2249.2005.02904.x","article-title":"GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males","volume":"142","author":"Tanriverdi","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaccao.2023.05.011_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/TCRM.S249208","article-title":"Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis","volume":"16","author":"Perrone","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jaccao.2023.05.011_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00345-020-03433-3","article-title":"Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice","volume":"39","author":"Davey","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.jaccao.2023.05.011_bib17","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/ijc.33397","article-title":"Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases","volume":"148","author":"George","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jaccao.2023.05.011_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3389\/fonc.2018.00543","article-title":"Retrospective analysis of patients with prostate cancer initiating GnRH agonists\/antagonists therapy using a German claims database: epidemiological and patient outcomes","volume":"8","author":"Hupe","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaccao.2023.05.011_bib19","first-page":"114","article-title":"Birth and maturation of cardio-oncology","volume":"1","author":"Bhatt","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.05.011_bib20","first-page":"619","article-title":"Common pathophysiology in cancer, atrial fibrillation, atherosclerosis, and thrombosis: JACC: CardioOncology state-of-the-art review","volume":"3","author":"Leiva","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.05.011_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/bju.15059","article-title":"Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists","volume":"126","author":"Cone","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.jaccao.2023.05.011_bib22","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.jaccao.2023.05.011_bib23","first-page":"2313","article-title":"Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer","volume":"184","author":"Smith","year":"2010","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jaccao.2023.05.011_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000345423","article-title":"Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233)","volume":"90","author":"Anderson","year":"2013","journal-title":"Urol Int"},{"key":"10.1016\/j.jaccao.2023.05.011_bib25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.clon.2012.09.010","volume":"25","author":"Mason","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jaccao.2023.05.011_bib26","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1111\/j.1464-410X.2012.11107.x","article-title":"Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide","volume":"110","author":"Axcrona","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.jaccao.2023.05.011_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.7_suppl.151","article-title":"Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: exploratory analysis of a randomized controlled trial","volume":"33","author":"Higano","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2023.05.011_bib28","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/cas.13600","article-title":"Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: a phase III study","volume":"109","author":"Ozono","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jaccao.2023.05.011_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2016.34.2_suppl.200","article-title":"Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts)","volume":"34","author":"Saad","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2023.05.011_bib30","first-page":"1199","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease","volume":"202","author":"Margel","year":"2019","journal-title":"J\u00a0Urol"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087323001710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087323001710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:57:35Z","timestamp":1762973855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087323001710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2666087323001710"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2023.05.011","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Effects of GnRH Antagonists Compared With Agonists in\u00a0Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2023.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}